tiotropium + BI 54903

**Tiotropium + BI 54903** is a discontinued fixed-dose combination intended for inhalation treatment of obstructive airway disorders such as asthma and respiratory tract disorders. The combination consists of tiotropium bromide, a long-acting muscarinic antagonist that primarily targets muscarinic M1 and M3 receptors, and BI 54903, a small molecule agonist of the glucocorticoid receptor (GR) with immunosuppressive effects. Tiotropium acts by blocking M3 receptors, leading to bronchial smooth muscle relaxation and bronchodilation, while BI 54903 is designed to provide anti-inflammatory activity by activating GR. Both drugs were developed by Boehringer Ingelheim, and the combination was designed to leverage complementary mechanisms: bronchodilation from tiotropium and anti-inflammatory effects from BI 54903, aiming for improved clinical outcomes in asthma and obstructive respiratory conditions. The combination’s development was discontinued after early-stage clinical trials[2][4][6].

Other names

tiotropium bromide + BI 54903